Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382987 | 0.90 | EPHX2 (0.53) | MGLLALDH1A1RAB9AEPHX2EPHX1 | |
| SCHEMBL2383573 | 0.87 | ALDH1A1 (0.61) | ALDH1A1RAB9AEPHX1GAA | |
| SCHEMBL4182633 | 0.86 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1 | |
| SCHEMBL4070011 | 0.86 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1 | |
| SCHEMBL4175464 | 0.86 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1 | |
| SCHEMBL31417142 | 0.85 | MAPT (0.53) | MGLLALDH1A1RAB9AEPHX2EPHX1 | |
| SCHEMBL12436790 | 0.82 | MGLL (0.48) | MGLLALDH1A1RAB9AEPHX2EPHX1 | |
| SCHEMBL3064575 | 0.82 | EPHX2 (0.47) | MGLLALDH1A1RAB9AEPHX2EPHX1 | |
| SCHEMBL31715470 | 0.81 | MGLL (0.53) | MGLLALDH1A1GAA | |
| SCHEMBL29157993 | 0.81 | DRD2 (0.52) | MGLLALDH1A1RAB9AEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588480-B1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | disclosed |
| EP-2588480-B1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | disclosed |
| US-9233965-B2 | 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta | SANOFI (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233965-B2 | 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta | SANOFI (FR) | 2016-01-12 | — | — | US | disclosed |
| US-20140336189-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-11-13 | — | — | US | disclosed |
| US-20140336189-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-11-13 | — | — | US | disclosed |
| US-8791119-B2 | 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| US-8791119-B2 | 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2588480-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF& xA; | SANOFI (FR) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-11 | — | — | US | disclosed |
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-11 | — | — | US | disclosed |
| WO-2011161537-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161537-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | WO | disclosed |
| EP-1940835-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1940835-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCN1, HCN2 | MGLL 2413/4885ALDH1A1 703/4885RAB9A 1799/4885 |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | PDE4B, PDE3B, PDE4A | MGLL 2650/4885ALDH1A1 1603/4885RAB9A 1990/4885 |
| US-20140336189-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCN1, HCN2 | MGLL 2413/4885ALDH1A1 703/4885RAB9A 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.